Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Abliva AB (publ)
  6. News
  7. Summary
    ABLI   SE0002575340

ABLIVA AB (PUBL)

(ABLI)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-11-30 am EST
0.1640 SEK   +0.61%
11/22Abliva AB Interim Report January – September 2022
AQ
11/22Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
11/15Biostock : áPatient perspective in focus in Abliva's phase II/III study
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Abliva publ : arranges Mitochondria Day on 16 September 2020

08/12/2020 | 05:31am EST

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m.4 p.m. CEST. The purpose of the day is to increase understanding of the enormous medical need within primary mitochondrial diseases, treatments under development, as well as the growing interest in investments in the area.

We begin by taking a closer look at what it's like to be a patient and a relative, and how health care experts work. Furthermore, representatives from the company will present Abliva's program in drug development, followed by exciting insights into clinical development and clinical studies with the help of our network of international experts. We conclude the day with a discussion on the views on, and conditions for, investments in projects for the development of medicines for rare diseases.

The program is designed to be of interest both for those who have a professional interest – in health care, research, or the media – as well as for patients, relatives, and the interested public. The Mitochondria Day is part of The World Mitochondrial Disease Week, which runs from 13 to 19 September. https://mitochondrialdiseaseweek.org.

The event is virtual, requires no pre-registration, and can be followed via link (to be sent out shortly). The recording will also be posted afterwards on Abliva's website, www.abliva.com. Some of the presentations/interviews will be held in Swedish and some in English. During the event you can ask questions via ir@abliva.com.

A warm welcome on 16 September!

© Modular Finance, source Nordic Press Releases

All news about ABLIVA AB (PUBL)
11/22Abliva AB Interim Report January – September 2022
AQ
11/22Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe..
CI
11/15Biostock : áPatient perspective in focus in Abliva's phase II/III study
AQ
09/19Biostock : áRaising awareness around patients with mitochondrial diseases
AQ
09/16Abliva to participate in World Mitochondrial Disease Week 2022
AQ
08/19Abliva AB Interim Report January – June 2022
AQ
08/19Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30,..
CI
08/10Biostock : áA new approach to mitochondrial diseases
AQ
07/29Amended number of shares and votes in Abliva AB (publ)
AQ
07/13Last day of trading with BTA in Abliva
AQ
More news
Financials
Sales 2022 0,15 M 0,01 M 0,01 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 172 M 16,3 M 16,3 M
Capi. / Sales 2022 1 140x
EV / Sales 2023
Nbr of Employees 8
Free-Float 92,2%
Chart ABLIVA AB (PUBL)
Duration : Period :
Abliva AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABLIVA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,16
Average target price
Spread / Average Target -
Managers and Directors
Ellen K. Donnelly Chief Executive Officer
Catharina Jz Johansson CFO, Secretary, VP-Investor Relations & Deputy CEO
David Laskow-Pooley Chairman
Eskil ElmÚr Chief Scientific Officer & VP-Discovery
Magnus Hansson Chief Medical Officer & VP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
ABLIVA AB (PUBL)-72.04%16
VERTEX PHARMACEUTICALS44.05%81 199
REGENERON PHARMACEUTICALS, INC.17.41%78 615
BIONTECH SE-36.54%39 760
WUXI APPTEC CO., LTD.-34.05%31 776
GENMAB A/S20.91%28 866